Advancing Sepsis Diagnostics—Journal of Clinical Medicine (JCM), Honors SeptiCyte RAPID* Study

  Immunexpress are delighted to announce that the study, “Validation of SeptiCyte® RAPID to Discriminate Sepsis from Non-Infectious Systemic Inflammation,” has been selected as an Editor’s Choice Paper for 2024 by the Journal of Clinical Medicine (JCM) MDPI Editorial Team. This honour underscores its importance in sepsis diagnostics and its clinical relevance. This research provides critical validation of SeptiCyte RAPID in assessing sepsis probability and distinguishing sepsis from SIRS in critically ill adult patients. The findings support its effectiveness under both Sepsis-2 and Sepsis-3 frameworks, delivering actionable results […]

SeptiCyte – Sepsis diagnosis technology

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. SeptiCyte® technology can assess a patients dysregulated immune response by quantifying and analysing gene expression signatures from whole blood, providing an accurate sepsis diagnosis

SeptiCyte RAPID – available for IVD use in Australia

Products are for Professional/Laboratory use only Diagnose Sepsis with more certainty in just one hour with SeptiCyte® RAPID, now available for IVD use in Australia.

Biocartis Announces Nine Idylla™ Studies Published at AMP 2022 Annual Meeting

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. Among the studies published, four studies on the Idylla™ GeneFusion Assay highlighted the strengths of Idylla™ testing including high accuracy, ease-of-use and rapid time-to-results.